Hyderabad News Desk

HER2-Negative Breast Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

 Breaking News
  • No posts were found

HER2-Negative Breast Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

October 10
01:35 2023
HER2-Negative Breast Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “HER2-Negative Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report

  • DelveInsight’s HER2-Negative Breast Cancer pipeline report depicts a robust space with 85+ active players working to develop 85+ pipeline therapies for HER2-Negative Breast Cancer treatment.
  • The leading companies working in the HER2-Negative Breast Cancer Market include AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others.
  • Promising HER2-Negative Breast Cancer Pipeline Therapies in the various stages of development include MM-121, Paclitaxel, BGB-290, AZD9833, Fulvestrant, Anastrozole, OP-1250, and others.
  • October 2023: Tvardi Therapeutics Incorporated announced a study of Phase 1 & 2 Clinical trias for TTI-101, Palbociclib, Aromatase inhibitor (AI), and Fulvestrant. The primary objective of Phase 2 will be to evaluate anti-tumor activity in participants who receive TTI-101 added to palbociclib or ribociclib and AI or fulvestrant.
  • October 2023: Kari Wisinski announced a study of Phase 1 & 2 Clinical trials for Gedatolisib and Talazoparib. This study is designed to determine the RP2D of gedatolisib in combination with talazoparib and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that is triple negative or BRCA1/2 positive (deficient).

 

Request a sample and discover the recent advances in HER2-Negative Breast Cancer Treatment Drugs @ HER2-Negative Breast Cancer Pipeline Report

 

In the HER2-Negative Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2-Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

HER2-Negative Breast Cancer Overview

HER2-Negative Breast Cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and/or progesterone along with no expression of the human epidermal growth factor receptor 2 (HER2). Immunohistochemistry (IHC) test and/or Fluorescent in situ hybridization (FISH) is done to find out if cancer cells have estrogen and progesterone receptors.

 

Find out more about HER2-Negative Breast Cancer Therapeutics Assessment @ HER2-Negative Breast Cancer Preclinical and Discovery Stage Products

 

HER2-Negative Breast Cancer Emerging Drugs Profile

  • Capivasertib + Fulvestrant: AstraZeneca
  • Dalpiciclib: Jiangsu HengRui Medicine

 

HER2-Negative Breast Cancer Pipeline Therapeutics Assessment

There are approx. 85+ key companies which are developing the HER2-Negative Breast Cancer therapies. The HER2-Negative Breast Cancer companies which have their HER2-Negative Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu HengRui Medicine.

 

Learn more about the emerging HER2-Negative Breast Cancer Pipeline Therapies @ HER2-Negative Breast Cancer Clinical Trials Assessment

 

Scope of the HER2-Negative Breast Cancer Pipeline Report

  • Coverage- Global
  • HER2-Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • HER2-Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • HER2-Negative Breast Cancer Companies- AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others.
  • HER2-Negative Breast Cancer Pipeline Therapies- MM-121, Paclitaxel, BGB-290, AZD9833, Fulvestrant, Anastrozole, OP-1250, and others.

 

Dive deep into rich insights for new drugs for HER2-Negative Breast Cancer Treatment, Visit @ HER2-Negative Breast Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. HER2-Negative Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. HER2-Negative Breast Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. HER2-Negative Breast Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Capivasertib + Fulvestrant: AstraZeneca
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II/III)
  13. Inavolisib: Roche
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Afuresertib + Fulvestrant: Laekna
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. HER2-Negative Breast Cancer Key Companies
  23. HER2-Negative Breast Cancer Key Products
  24. HER2-Negative Breast Cancer- Unmet Needs
  25. HER2-Negative Breast Cancer- Market Drivers and Barriers
  26. HER2-Negative Breast Cancer- Future Perspectives and Conclusion
  27. HER2-Negative Breast Cancer Analyst Views
  28. HER2-Negative Breast Cancer Key Companies
  29. Appendix

 

For further information on the HER2-Negative Breast Cancer Pipeline therapeutics, reach out to HER2-Negative Breast Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

Categories